Testing Data
(Figure A. PE conjugated Mouse anti Human CD11c and Amethyst Orange conjugated Mouse IgG2a isotype control . Figure B. PE conjugated Mouse anti Human CD11c and Amethyst Orange conjugated Mouse anti Human HLA DP DQ DR . All experiments performed on human blood gated on live single mononuclear cells, in the presence of 10% human serum. Data acquired on the ZE5 Cell Analyzer)
Mouse anti-Human HLA DP DQ DR Monoclonal Antibody
Mouse Anti Human HLA DP DQ DR: Amethyst Orange
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood
1% Bovine Serum Albumin
Storage in frost-free freezers is not recommended.
This product should be stored undiluted.
This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody.
This product contains a precipitate we recommend microcentrifugation before use.
Testing Data
(Figure A. PE conjugated Mouse anti Human CD11c and Amethyst Orange conjugated Mouse IgG2a isotype control . Figure B. PE conjugated Mouse anti Human CD11c and Amethyst Orange conjugated Mouse anti Human HLA DP DQ DR . All experiments performed on human blood gated on live single mononuclear cells, in the presence of 10% human serum. Data acquired on the ZE5 Cell Analyzer)
Testing Data
(Figure A. PE conjugated Mouse anti Human CD11c and Amethyst Orange conjugated Mouse IgG2a isotype control . Figure B. PE conjugated Mouse anti Human CD11c and Amethyst Orange conjugated Mouse anti Human HLA DP DQ DR . All experiments performed on human blood gated on live single mononuclear cells, in the presence of 10% human serum. Data acquired on the ZE5 Cell Analyzer)
Testing Data
(Figure A. RPE conjugated Mouse anti Human CD11c and FITC conjugated Mouse IgG2a isotype control . Figure B. RPE conjugated Mouse anti Human CD11c and FITC conjugated Mouse anti Human HLA DP/DQ/DR . All experiments performed on human Peripheral blood mononuclear cells in the presence of human SeroBlock .)
Testing Data
(Figure A. RPE conjugated Mouse anti Human CD11c and FITC conjugated Mouse IgG2a isotype control . Figure B. RPE conjugated Mouse anti Human CD11c and FITC conjugated Mouse anti Human HLA DP/DQ/DR . All experiments performed on human Peripheral blood mononuclear cells in the presence of human SeroBlock .)
Testing Data
(FigureA. FITC conjugated Mouse anti Human CD86 and RPE conjugated Mouse IgG2a isotype control > Figure B. FITC conjugated Mouse anti Human CD86 and RPE conjugated Mouse anti Human HLA DP/DQ/DR . All experiments performed on human Peripheral blood mononuclear cells in the presence of human SeroBlock .)
Testing Data
(FigureA. FITC conjugated Mouse anti Human CD86 and RPE conjugated Mouse IgG2a isotype control > Figure B. FITC conjugated Mouse anti Human CD86 and RPE conjugated Mouse anti Human HLA DP/DQ/DR . All experiments performed on human Peripheral blood mononuclear cells in the presence of human SeroBlock .)
Testing Data
(Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the evaluation of MHC class II expression on dendritic cells by flow cytometry.Image caption:Time course of DC differentiation from H1 hESC. Cells were harvested from cultures at various time points and analysed by flow cytometry for the onset of hematopoiesis and the appearance of DC. (a) Cells harvested at day 20 of culture showing expressing of CD45 but lack of myeloid commitment, as evidenced by staining for CD13, CD14, and CD11c. Open histograms show levels of background staining using isotype-matched control antibodies. (b) Appearance of CD45int cells at day 27 of culture, accompanied by the upregulation of myeloid-specific markers. (c) Photomicrograph, taken at day 28 of culture, showing the morphology of DC, including veils of cytoplasm and long dendrites (inset) (×40 magnification). (d) Cells harvested at day 33 of culture, showing the appearance of a CD45hi population containing predominantly DC progenitors expressing CD14, CD11c, CD86 and MHC class I. (e) Phenotype of immature and mature H1-DCs compared with human moDC. DCs were cultured either in medium alone or medium supplemented with the maturation cocktail and stained for MHC class II, the maturation marker CD83 and classical costimulatory molecules. Dead cells were excluded from the analysis using 7-AAD. Dashed histograms show the phenotype of immature DCs while the filled histograms represent mature DCs. Open histograms depict background staining using isotype-matched controls.From: Kathryn M. Silk, Alison J. Leishman, Kevin P. Nishimoto, Anita Reddy, and Paul J. Fairchild, “Rapamycin Conditioning of Dendritic Cells Differentiated from Human ES Cells Promotes a Tolerogenic Phenotype,”Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 172420, 11 pages, 2012.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the evaluation of MHC class II expression on dendritic cells by flow cytometry.Image caption:Time course of DC differentiation from H1 hESC. Cells were harvested from cultures at various time points and analysed by flow cytometry for the onset of hematopoiesis and the appearance of DC. (a) Cells harvested at day 20 of culture showing expressing of CD45 but lack of myeloid commitment, as evidenced by staining for CD13, CD14, and CD11c. Open histograms show levels of background staining using isotype-matched control antibodies. (b) Appearance of CD45int cells at day 27 of culture, accompanied by the upregulation of myeloid-specific markers. (c) Photomicrograph, taken at day 28 of culture, showing the morphology of DC, including veils of cytoplasm and long dendrites (inset) (×40 magnification). (d) Cells harvested at day 33 of culture, showing the appearance of a CD45hi population containing predominantly DC progenitors expressing CD14, CD11c, CD86 and MHC class I. (e) Phenotype of immature and mature H1-DCs compared with human moDC. DCs were cultured either in medium alone or medium supplemented with the maturation cocktail and stained for MHC class II, the maturation marker CD83 and classical costimulatory molecules. Dead cells were excluded from the analysis using 7-AAD. Dashed histograms show the phenotype of immature DCs while the filled histograms represent mature DCs. Open histograms depict background staining using isotype-matched controls.From: Kathryn M. Silk, Alison J. Leishman, Kevin P. Nishimoto, Anita Reddy, and Paul J. Fairchild, “Rapamycin Conditioning of Dendritic Cells Differentiated from Human ES Cells Promotes a Tolerogenic Phenotype,”Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 172420, 11 pages, 2012.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the treatment on monocytes in vitrodetection of MHC class II onImage caption:Ligand engagement of HLA class II molecules up regulates MyD88, IL-1R1, and TNF-? in CD14+ human monocytes treated with SEB, SEA, or mAb directed against MHC-class II molecules. (A) Transcriptional activation of MyD88, IL-1R1AcP and TNF-? in HLA-DR positive primary monocytes treated with 200 ng SEB/ml (optimum dose), mAbs (10 µg/ml, optimum dose) directed against MHC-class II molecule (anti-DR-DP-DQ or LB3.1) or unrelated control antibody OKT3 was examined by semi-quantitative RT-PCR. Data shown is one of 3 similar experiments; (B) Agonists binding to TLR4 or HLA class II molecules on CD14+ monocytes induced transcriptional up regulation of MyD88. Real time RT-PCR was used to determine relative expression of MyD88 normalized to the expression of ?-actin. Expression levels are determined as means ± SD. Data presented as one of 3 similar experiments. Significance compared to untreated control (*) was assigned as P?0.0001. (C) MHC class II molecule dependence of SEB- induced TNF- ? gene expression. Pretreatment of monocytes in ice with anti-DR-DP-DQ at optimum dose (10 ug/ml) followed by SEB stimulation resulted in reduced TNF- ? gene expression. Transcriptional activation of TNF- ? expression normalized to the expression of ?-actin. Expression levels of TNF- ? are expressed as means ± SD. Significance was assigned (*) or (**) as P values ?0.003 comparing untreated vs treatment groups with anti-DR-DP-DQ, SEB or SEB vs anti-DR-DP-DQ+SEB respectively. (D) Confocal images show expression of HLA-DR (green) and intracellular MyD88 (red) proteins in CD14+ monocytes treated with HLA class II- ligands or control antibody OKT3 for 16 h; Scale bar = 5 ?m; (E) intracellular expression of MyD88 protein in activated monocytes. Primary monocytes (CD14+, CD3-) were activated as described earlier, permeabilized and labeled with primary MyD88 antibody followed by PE-labeled secondary antibody and analyzed by flow cytometry. Histogram represents a MHC class II ligand-induced increase in expression of MyD88 protein compared to non-MHC class II ligand (OKT3).From: Kissner TL, Ruthel G, Alam S, Ulrich RG, Fernandez S, et al. (2011) Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules.PLoS ONE 6(1): e15985.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the treatment on monocytes in vitrodetection of MHC class II onImage caption:Ligand engagement of HLA class II molecules up regulates MyD88, IL-1R1, and TNF-? in CD14+ human monocytes treated with SEB, SEA, or mAb directed against MHC-class II molecules. (A) Transcriptional activation of MyD88, IL-1R1AcP and TNF-? in HLA-DR positive primary monocytes treated with 200 ng SEB/ml (optimum dose), mAbs (10 µg/ml, optimum dose) directed against MHC-class II molecule (anti-DR-DP-DQ or LB3.1) or unrelated control antibody OKT3 was examined by semi-quantitative RT-PCR. Data shown is one of 3 similar experiments; (B) Agonists binding to TLR4 or HLA class II molecules on CD14+ monocytes induced transcriptional up regulation of MyD88. Real time RT-PCR was used to determine relative expression of MyD88 normalized to the expression of ?-actin. Expression levels are determined as means ± SD. Data presented as one of 3 similar experiments. Significance compared to untreated control (*) was assigned as P?0.0001. (C) MHC class II molecule dependence of SEB- induced TNF- ? gene expression. Pretreatment of monocytes in ice with anti-DR-DP-DQ at optimum dose (10 ug/ml) followed by SEB stimulation resulted in reduced TNF- ? gene expression. Transcriptional activation of TNF- ? expression normalized to the expression of ?-actin. Expression levels of TNF- ? are expressed as means ± SD. Significance was assigned (*) or (**) as P values ?0.003 comparing untreated vs treatment groups with anti-DR-DP-DQ, SEB or SEB vs anti-DR-DP-DQ+SEB respectively. (D) Confocal images show expression of HLA-DR (green) and intracellular MyD88 (red) proteins in CD14+ monocytes treated with HLA class II- ligands or control antibody OKT3 for 16 h; Scale bar = 5 ?m; (E) intracellular expression of MyD88 protein in activated monocytes. Primary monocytes (CD14+, CD3-) were activated as described earlier, permeabilized and labeled with primary MyD88 antibody followed by PE-labeled secondary antibody and analyzed by flow cytometry. Histogram represents a MHC class II ligand-induced increase in expression of MyD88 protein compared to non-MHC class II ligand (OKT3).From: Kissner TL, Ruthel G, Alam S, Ulrich RG, Fernandez S, et al. (2011) Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules.PLoS ONE 6(1): e15985.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the evaluation of HLA DR expression on dendritic cells by flow cytometry.Image caption:Upregulation of DC class II expression by paclitaxel is not mediated via TLR-4. DC were cultured for 2 h with LPS or paclitaxel in the presence or absence of anti-TLR-4 Abs prior to washing and reculture for a further 24 h. Anti-TLR4 antibody did reduce class II expression after exposure to LPS, but not to paclitaxel at high dose. Numbers in parenthesis represent MFI of class II detection. Data is representative of 3 independent experiments from 3 donors.From: John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, Pandha H. Differential effects of Paclitaxel on dendritic cell function.BMC Immunol. 2010 Mar 19;11:14.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the evaluation of HLA DR expression on dendritic cells by flow cytometry.Image caption:Upregulation of DC class II expression by paclitaxel is not mediated via TLR-4. DC were cultured for 2 h with LPS or paclitaxel in the presence or absence of anti-TLR-4 Abs prior to washing and reculture for a further 24 h. Anti-TLR4 antibody did reduce class II expression after exposure to LPS, but not to paclitaxel at high dose. Numbers in parenthesis represent MFI of class II detection. Data is representative of 3 independent experiments from 3 donors.From: John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, Pandha H. Differential effects of Paclitaxel on dendritic cell function.BMC Immunol. 2010 Mar 19;11:14.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the treatment of human mononuclear cells in vitro.Image caption:Inhibition of proliferation by anti-MHC class II antibody. Mononuclear cells from cord blood (?) or adult PBMC (?) were preincubated with MAb MCA477, and assays of proliferation to different antigens were carried out. Inhibition was expressed as the SI for treated cells compared to that for untreated cells, which was normalized to 100%. Each bar represents the mean and standard deviation from three assays.From: Chia JS, You CM, Hu CY, Chiang BL, Chen JY.Human T-cell responses to the glucosyltransferases of Streptococcus mutans. Clin Diagn Lab Immunol. 2001 Mar;8(2):441-5.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the treatment of human mononuclear cells in vitro.Image caption:Inhibition of proliferation by anti-MHC class II antibody. Mononuclear cells from cord blood (?) or adult PBMC (?) were preincubated with MAb MCA477, and assays of proliferation to different antigens were carried out. Inhibition was expressed as the SI for treated cells compared to that for untreated cells, which was normalized to 100%. Each bar represents the mean and standard deviation from three assays.From: Chia JS, You CM, Hu CY, Chiang BL, Chen JY.Human T-cell responses to the glucosyltransferases of Streptococcus mutans. Clin Diagn Lab Immunol. 2001 Mar;8(2):441-5.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human HLA DP/DQ/DR antibody, clone WR18 used for the evaluation of HLA class II histocompatibility antigen expression on cell populations by flow cytometry.Image caption:DC differentiation from H1 hESC.Cells were harvested from cultures at various time points and analysed by flow cytometry for the onset of hematopoiesis and the appearance of DC. (e) Phenotype of immature and mature H1-DCs compared with human moDC. DCs were cultured either in medium alone or medium supplemented with the maturation cocktail and stained for MHC class II, the maturation marker CD83 and classical costimulatory molecules. Dead cells were excluded from the analysis using 7-AAD. Dashed histograms show the phenotype of immature DCs while the filled histograms represent mature DCs. Open histograms depict background staining using isotype-matched controls.From: Silk KM, Leishman AJ, Nishimoto KP, Reddy A, Fairchild PJ.Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype.J Biomed Biotechnol. 2012;2012:172420.doi: 10.1155/2012/172420.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
Testing Data
(Mouse anti Human HLA DP/DQ/DR antibody, clone WR18 used for the evaluation of HLA class II histocompatibility antigen expression on cell populations by flow cytometry.Image caption:DC differentiation from H1 hESC.Cells were harvested from cultures at various time points and analysed by flow cytometry for the onset of hematopoiesis and the appearance of DC. (e) Phenotype of immature and mature H1-DCs compared with human moDC. DCs were cultured either in medium alone or medium supplemented with the maturation cocktail and stained for MHC class II, the maturation marker CD83 and classical costimulatory molecules. Dead cells were excluded from the analysis using 7-AAD. Dashed histograms show the phenotype of immature DCs while the filled histograms represent mature DCs. Open histograms depict background staining using isotype-matched controls.From: Silk KM, Leishman AJ, Nishimoto KP, Reddy A, Fairchild PJ.Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype.J Biomed Biotechnol. 2012;2012:172420.doi: 10.1155/2012/172420.This image is from an open access article distributed under the terms of the Creative Commons Attribution License.)
The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In humans, this complex is referred to as the human leukocyte antigen (HLA) region. There are 3 major MHC class II proteins encoded by the HLA which are HLA DP, HLA DQ and HLA DR.
Similar Products
Product Notes
The HLA DP DQ DR (Catalog #AAA225865) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Mouse Anti Human HLA DP DQ DR: Amethyst Orange reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's HLA DP DQ DR can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS). FC/FACS: Max. Dilution: Neat Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood. Researchers should empirically determine the suitability of the HLA DP DQ DR for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "HLA DP DQ DR, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
